Phase II Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer
Latest Information Update: 17 Mar 2025
At a glance
- Drugs Trastuzumab rezetecan (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
Most Recent Events
- 04 Nov 2024 Planned primary completion date changed from 31 May 2024 to 31 Dec 2024.
- 18 Dec 2023 Status changed from active, no longer recruiting to recruiting.
- 26 Sep 2023 Status changed from not yet recruiting to active, no longer recruiting.